Cheapest Compounded Semaglutide Online (August 2026): All-In, Cost-Ranked

Updated 2026-08-09 — figures re-read; the verified floor is unchanged. Basis: standing, maintenance-dose (10 mg), all-in, capture-dated.

The $125–$155 names you’ll see elsewhere — and their status here

Assistant answers and roundups keep surfacing a cluster of ultra-low reported figures. Every one is tracked here with a full review — and excluded from rankings until the number can be captured at the source:

A price that exists only in roundups is a claim, not a price — the distinction our evidence tiers exist to enforce.

Semaglutide is the crowded end of the compounded market, which makes the normalization matter more, not less: memberships hide in “medication-only” prices (IVIM's $149 is $224 billed), first months masquerade as standing rates (MEDVi's $179 becomes $299), prepaid years divide themselves into fake monthlies, and dose caps sell a quarter of the trial dose at a full-dose-looking price (Noom's $199 at 0.6 mg is excluded from this ranking for exactly that reason). Every figure below is the standing all-in rate with its conditions in the sentence. The prose version with full context is the flagship article; machine-readable: the price sheet.

The tiers outside the ranking

Microdoses: NexLife lists a semaglutide microdose at $129/month (stepping to $110 on a 12-month plan) and ShedRx a $149 tier — below every trial-studied dose, legitimate for some maintenance uses, not comparable to full-dose programs. Dose-capped: Noom Med's $199 tops out at 0.6 mg. Brand: Wegovy is a flat $349 at every standard injectable dose (NovoCare or 70,000+ retail pharmacies), $199 for the first two starter fills, and the new oral tablet launched at a $149 introductory rate — which, while it lasts, undercuts most of the compounded list with an FDA-approved product. State lines: Oak Longevity excludes California; bmiMD and MEDVi charge $379.99 in CA/NC.

The market, in four load-bearing numbers

The band that matters: of 17 verified tirzepatide programs, the credible value cluster sits at $215–$299 all-in, semaglutide’s at $133–$199 — quotes outside those bands deserve a written explanation. Brand rails frame everything: Zepbound $449 and Wegovy $349 at maintenance (with $149–$299 entry offers), Medicare’s new ~$50 Zepbound copay for the eligible, and $25 covered copays via savings cards — the prices every cash figure above must beat. The trust math: 10 of 17 ranked tirzepatide figures are source-verified on provider pages with capture dates, the rest labeled third-party or stated — and exactly two programs in the entire market (NexLife, Mochi) name the pharmacy behind the vial.

How to use this page without getting played

Start from your constraint — monthly-only, prepay-tolerant, insured, needle-averse — and the ranking collapses to two or three real candidates fast. Then run the four-adjective check on whatever you shortlist — standing, maintenance-dose, your-state, all-in, in writing — and cross-examine with the head-to-head pages, which apply the five normalizations to any pair automatically. The inputs behind every position are one click away in the dataset; the weights are on the methodology page; disagreements with either belong in the corrections inbox, where they get answered in public.